COMP <GO>
GANX vs XLO // EV/EBITDA & P/E VALUATION
Gain Therapeutics Inc. (NASDAQ) VS. Xilio Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: GANX 1
— XLO 1
■ METRIC PARITY
LAST: $1.13 (-5.04%) • MKT CAP: $51.9M
valuation
—
LAST: $8.03 (+3.35%) • MKT CAP: $51.1M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GANX VS. XLO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GANX | XLO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -10.78% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 180.00% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 0.20 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 4/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 34.0 | 42.1 | -8.08 | XLO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $51.9M | $51.1M | $808.1K | GANX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GANX REV | XLO REV | GANX GROSS % | XLO GROSS % | GANX FCF | XLO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $43.8M | — | — | -$18.5M | -$5.5M |
| FY 2024 | $0 | $6.3M | — | — | -$18.9M | -$18.4M |
| FY 2023 | $55.2K | $0 | — | — | -$18.9M | -$68.6M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GANX // BETA —
XLO // BETA —